Literature DB >> 33611770

Overcoming biological barriers to improve solid tumor immunotherapy.

Anvay Ukidve1,2, Katharina Cu1,2, Ninad Kumbhojkar1,2, Joerg Lahann3, Samir Mitragotri4,5.   

Abstract

Cancer immunotherapy has been at the forefront of therapeutic interventions for many different tumor types over the last decade. While the discovery of immunotherapeutics continues to occur at an accelerated rate, their translation is often hindered by a lack of strategies to deliver them specifically into solid tumors. Accordingly, significant scientific efforts have been dedicated to understanding the underlying mechanisms that govern their delivery into tumors and the subsequent immune modulation. In this review, we aim to summarize the efforts focused on overcoming tumor-associated biological barriers and enhancing the potency of immunotherapy. We summarize the current understanding of biological barriers that limit the entry of intravascularly administered immunotherapies into the tumors, in vitro techniques developed to investigate the underlying transport processes, and delivery strategies developed to overcome the barriers. Overall, we aim to provide the reader with a framework that guides the rational development of technologies for improved solid tumor immunotherapy.
© 2021. Controlled Release Society.

Entities:  

Keywords:  Adoptive cell transfer; Biomaterials; Immune modulation; Immunotherapy; Nanoparticles; Solid tumor

Mesh:

Year:  2021        PMID: 33611770     DOI: 10.1007/s13346-021-00923-8

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  204 in total

1.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

Review 2.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

3.  Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Authors:  Merry Jennifer Markham; Kerri Wachter; Neeraj Agarwal; Monica M Bertagnolli; Susan Marina Chang; William Dale; Catherine S M Diefenbach; Carlos Rodriguez-Galindo; Daniel J George; Timothy D Gilligan; R Donald Harvey; Melissa L Johnson; Randall J Kimple; Miriam A Knoll; Noelle LoConte; Robert G Maki; Jane Lowe Meisel; Jeffrey A Meyerhardt; Nathan A Pennell; Gabrielle B Rocque; Michael S Sabel; Richard L Schilsky; Bryan James Schneider; William D Tap; Robert G Uzzo; Shannon Neville Westin
Journal:  J Clin Oncol       Date:  2020-02-04       Impact factor: 44.544

4.  A dendritic cell multitasks to tackle cancer.

Authors:  Marianne Burbage; Sebastian Amigorena
Journal:  Nature       Date:  2020-08       Impact factor: 49.962

Review 5.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 6.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

Review 7.  Cancer immunotherapy comes of age and looks for maturity.

Authors:  Amanda Finck; Saar I Gill; Carl H June
Journal:  Nat Commun       Date:  2020-07-03       Impact factor: 14.919

Review 8.  Oncolytic Viruses in Cancer Treatment: A Review.

Authors:  Sean E Lawler; Maria-Carmela Speranza; Choi-Fong Cho; E Antonio Chiocca
Journal:  JAMA Oncol       Date:  2017-06-01       Impact factor: 31.777

9.  A decade of immune-checkpoint inhibitors in cancer therapy.

Authors:  Caroline Robert
Journal:  Nat Commun       Date:  2020-07-30       Impact factor: 14.919

Review 10.  A guide to cancer immunotherapy: from T cell basic science to clinical practice.

Authors:  Alex D Waldman; Jill M Fritz; Michael J Lenardo
Journal:  Nat Rev Immunol       Date:  2020-05-20       Impact factor: 53.106

View more
  2 in total

Review 1.  Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.

Authors:  Tyrillshall S T Damiana; Simone U Dalm
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

2.  Versatile and Robust Method for Antibody Conjugation to Nanoparticles with High Targeting Efficiency.

Authors:  Indra Van Zundert; Maria Bravo; Olivier Deschaume; Pierre Cybulski; Carmen Bartic; Johan Hofkens; Hiroshi Uji-I; Beatrice Fortuni; Susana Rocha
Journal:  Pharmaceutics       Date:  2021-12-14       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.